Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies™ (HSB-1940) against PD-1, by combining Quatramers™…

Posted: December 2, 2022 at 12:43 am

Collaboration allows Hillstream to enter the rapidly growing Immuno-oncology therapeutics market

See more here:
Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies™ (HSB-1940) against PD-1, by combining Quatramers™...

Related Posts